chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Client reports on the morning after receiving her vaccine she experienced  left sided sore throat pain that progressed to spine pain and swelling at injection site up her neck and to L eye area. Symptoms lasted approximately 3-4 days.  "It was concerning enough that I don't want to get the second vaccine".
A couple minutes after injections pt pass out for roughly 2-3 minutes then came too.
This case was reported by a lawyer and described the occurrence of Arthralgia in a male subject of unspecified age who was vaccinated with LYMERIX. A physician or other health care professional has not verified this report. On an unspecified date the subject received unspecified dose of LYMERIX (unknown). At an unknown time after vaccination with LYMERIX, the subject experienced Arthralgia, back pain, swelling, rheumatological symptoms, neurological impairment, cognitive impairment, autoimmune disease, decreased ability to perform daily activities and decreased activity level. At the time of reporting the outcome of the events was unspecified. This information was received via a statement of injuries. Follow-up information was received on 17 December 2008 via an interview between the subject and attorney(s). The subject was vaccinated with LYMERIX in April 1999, May 1999 and April 2000, In approximately 2001 he developed premature ejaculation and erectile dysfunction. Between 2001 and 2003 he developed difficulty writing and joint stiffness. In approximately 2005 he developed thumb joint pain. In approximately 2006 he developed left arm neck and numbness. treatment included VIAGRA. The events were unresolved at the time of this report. This case was assessed as medically significant based upon follow up information.
Itchy hives; Rash all over body; A spontaneous report was received from a health care professional concerning a 20-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) experienced multiple events of rash all over body and itchy hives.  The patient's medical history was not provided. No concomitant medications were reported.  On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot# 026O20A, Exp. unknown). On the same day, patient experienced rash all over body and itchy hives. The treatment information included Benadryl. Symptoms did not subside after taking Benadryl. It was confirmed that the patient was not pregnant.   The Action taken with mRNA-1273 in response to the events was unknown.   The outcome for the events, rash all over body and itchy hives was not resolved.; Reporter's Comments: This case concerns a 20-year-old, female patient, who experienced a non-serious unexpected event of urticaria and non-serious expected event of rash. The events occurred 1 day (3 Hrs.) after first dose of mRNA-1273, lot # 026O20A. Treatment included Benadryl. Based on the current available information and temporal association between the use of the product and onset of the events a causal relationship cannot be excluded.
fever, joint aches, body aches <12hrs p/vax;cheeks red rash resolved; fever/achiness from 1MAR96 7AM to 2MAR96 PM;
Itchiness on right outer thigh; Red lines on right outer thigh; A spontaneous report was received from a consumer concerning himself, a male patient of unknown age, who developed itchiness of the right outer thigh [Pruritis] and red lines of right outer thigh [Erythema].   The patient's medical history was not provided. Concomitant product use was not provided by the reporter.   On 30-Dec-2020, one day prior to the onset of the symptoms, the patient received one of two planned doses of mRNA-1273 (037K20A) intramuscularly in an unknown injection site for prophylaxis of COVID-19 infection.   The patient reported he started to experience itchiness on the right outer thigh and observed four red lines on the same thigh approximately 3 inches in length.  Treatment information was not provided.   Action taken with mRNA-1273 in response to the events was not provided.   The outcomes of the events were not reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Left axila pain/discomfort, patient believes to be lymph note, began after the vaccination and has continued for a week
Started menstruating the day after first shot which was 1.5 weeks early.; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 05Apr2021 at 11:00 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin and sulfa. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 06Apr2021 at 12:00, the patient experienced menstruating the day after the first shot which was 1.5 weeks early. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event early menstruation was recovered on an unknown date.  No follow-up attempts are needed. No further information is expected.
Pregnant; Headache; Sore arm; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant), HEADACHE (Headache) and MYALGIA (Sore arm) in a 35-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     Concurrent medical conditions included Pregnancy since 12-Nov-2020. Concomitant products included DULOXETINE HYDROCHLORIDE (DULOXETINE DR) for Anxiety depression, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for Pregnancy.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 03-Nov-2020 and the estimated date of delivery was 10-Aug-2021. On 28-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant), HEADACHE (Headache) and MYALGIA (Sore arm). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twelfth week of the pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant), HEADACHE (Headache) and MYALGIA (Sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information not provided.
Swelling arm of injection; Sore arm of injection; itchy at site of injection; Pinkish at site of injection; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING, PAIN IN EXTREMITY, VACCINATION SITE PRURITUS, and VACCINATION SITE ERYTHEMA in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, the patient experienced PERIPHERAL SWELLING, PAIN IN EXTREMITY, VACCINATION SITE PRURITUS, and VACCINATION SITE ERYTHEMA. At the time of the report, PERIPHERAL SWELLING, PAIN IN EXTREMITY, VACCINATION SITE PRURITUS, and VACCINATION SITE ERYTHEMA outcome was unknown. Not Provided          No relevant concomitant medications were provided.  The patient was inquiring if the polio vaccine interfere with the Covid-19 vaccination. Further, the patient stated that she had a medical appointment on 15-Apr-2021 to receive an injection. No treatment information was provided.
Nothing right away but within a few weeks I developed tingling in my right leg which has grown to unstoppable tremors  in my right leg and foot plus slight tremors in my  right hand.  I was also diagnosed with tachycardia and bradycardia and now have a pacemaker.
12/6/99:Pt. rcvd DTAP booster and developed redness and swelling gradually noted over 48 hrs.
Started off with a sore arm and I started getting a headache and falling asleep that same day. I was so tired that I felt like I hadn't gotten a good sleep in a few days. A few weeks later I developed a cough and it has not gone away since. It is intermittent and it may be there one week and then gone the next. There are times I am coughing so bad that I cannot breath and then an hour later I am perfectly normal.
A pharmacist and mother of the patient reported that her 9 month old son received his second dose  of Prevnar on 05/24/02.  That same day, he developed a rash which started on his legs and by the next day covered his entire body. He also had a fever of 101.9 degrees F. She gave her son Tylenol and Motrin. On 05/30/02, she reported that the rash was very faint." No further information was available at the date of the report.
Get that shot. I had them/ suspected vaccination failure; I had them; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional case details were reported as follows: The patient reported case for himself or herself. The age at vaccination was not reported. The patient got that shot and had them. The patient was going to ask about another shot for himself or herself. The patient stated that for years after patient got them and would feel pain deep down in that area, but forget that he or she was not into pain. This case was considered as suspected vaccination failure, as details regarding completion of primary vaccination schedule, laboratory test confirmation and time to onset for shingles were unknown at the time of reporting. The follow up was not required.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR175994:same reporter
Patient was given second dose three weeks early, first dose on vaccine card 2/09/2022 (this info was not in database). Patient is homeless and no contact number or address to follow up with patient.
She developed prolonged crying that started right after the immunizations and continued the next 3 days.  She had fever to 103F that lasted 4 days.  She was seen in our office on 2/11/2008 and was evaluated for infection (lab tests below).  She was very irritable but her exam was otherwise normal.  No source of infection was found.  No antibiotics were given and the fever and irritability was resolved when she was rechecked today (2/13/2008).  It is unclear whether this was due to her immunizations or was viral.
10 patients received Moderna vaccine that had thawed out and then refroze; 10 patients received Moderna vaccine that had thawed out and then refroze; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT STORAGE ERROR (10 patients received Moderna vaccine that had thawed out and then refroze), POOR QUALITY PRODUCT ADMINISTERED (10 patients received Moderna vaccine that had thawed out and then refroze) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT STORAGE ERROR (10 patients received Moderna vaccine that had thawed out and then refroze), POOR QUALITY PRODUCT ADMINISTERED (10 patients received Moderna vaccine that had thawed out and then refroze) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT STORAGE ERROR (10 patients received Moderna vaccine that had thawed out and then refroze), POOR QUALITY PRODUCT ADMINISTERED (10 patients received Moderna vaccine that had thawed out and then refroze) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT STORAGE ERROR (10 patients received Moderna vaccine that had thawed out and then refroze) and POOR QUALITY PRODUCT ADMINISTERED (10 patients received Moderna vaccine that had thawed out and then refroze).    This case contains information for the 8th of 10 patients described by the reporter.  Concomitant Medication use information was not provided by reporter.  Patient did not have information about previous COVID-19 vaccination doses.  It was unknown if patient receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  10 patients received Moderna vaccine that had thawed out and then refroze. All the patients were adults. The patients did not report other side effects.  Treatment Medication use information was not provided by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-743056 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-743056:Master case
Systemic: Fainting / Unresponsive-Severe, Additional Details: Patient remembered sitting down in a chair for observation, then slumped forward while on his phone. He did not remember falling over and was alert and oriented right away. Emergency services were called as he sustained an injury during his fall.
Rash on arm about 7 days after 1st dose; This is a spontaneous report from a contactable consumer (patient). A 22-years-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, formulation: solution for injection) via an unspecified route of administration, administered in arm left on 11May2021 17:00 (at the age of 22-years-old) as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced rash on arm about 7 days after first dose on 18May2021 09:00. The patient did not receive any treatment for the adverse event. The outcome of the event was recovering.  Information on the lot/batch number has been requested.
Chills, fever, aching joints, nausea & headache. Large local reaction at injection site.
Menstrual bleeding post menopause after Modena booster shot. Last period was March 2020.
pt recvd vax & 4 days p/vax exp paresthesia face, burning lt arm & leg, dec reflexes, slurred speech;
Information has been received on 21-NOV-2016 from a registered nurse referring to a 5 year old female patient. The patient's concurrent conditions and medical history were not reported. On 10-NOV-2016 the patient was vaccinated with PROQUAD lot # L045676, expiration 09-MAY-2017, 0.5 ml, subcutaneous. Other suspect therapies included FLUZONE and KINRIX administered during same office visit on 10-NOV-2016. Concomitant therapies included sodium fluoride, vitamins (unspecified). On 18-NOV-2016, the patient's mother contacted the office reporting that the patient experienced dark urine that was sinking to the bottom of the toilet. On 21-NOV-2016, the patient was seen by a physician's assistant and a urinalysis was done. The urinalysis results showed urine that was brown, turbid, bilirubin 1 +, blood 1+, protein 3+ and trace leukocytes. The registered nurse reported the patient was to return for unspecified blood tests and an ultrasound, later in the day, on 21-NOV-2016. The registered nurse reported the patient had not experienced pain or fever. No further information was provided. The outcome of the adverse events was unknown. The causality was not reported. Additional information has been requested.
This spontaneous case reported by a consumer, describes the occurrence of injection site irritation ("hive-like" bump a couple of inches below the injection site) and injection site rash (injection site rash formed a 6-inch diameter around the injection site) in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. The patient's past medical history included no adverse event. On an unknown date, patient received dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced injection site irritation ("hive-like" bump a couple of inches below the injection site) and injection site rash (injection site rash formed a 6-inch diameter around the injection site). At the time of the report, injection site irritation ("hive-like" bump a couple of inches below the injection site) and injection site rash (injection site rash formed a 6-inch diameter around the injection site): resolved. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. No concomitant information and treatment information provided.
Pt was admitted to hospital on 9/24/08.  No known exposure to chickenpox.  On 10/30/2008 he developed small  vesicopapular rashes with red base initially on face ( about 5) and trunk (about 5 in front, non in back);  on in upper extrem and only 1 in R leg.  Had slight headache the night before, no fever.  Started on ACYCLOVIN on 11/1/08.  Lesions dry except for 1 in R leg.
4:30 AM T-103.5, Rt. arm swollen and sore, mom giving Advil 200mg q6 hr. for fever, c/o nausea, will not eat or drink. Feels real bad according to mom referred to MD or ER for eval of fever. 103-104 and feeling really bad.
Client complains of severe itching, no rash noted.  The itching started mild on evening after receiving the Hepatitis B vaccination.  He also complains that his urine is dark orange.  Client complains that he experienced two episodes of lightheadedness.  He took benadryl Monday morning prior to coming in to report his adverse event.
had  shingles vaccine and get shingles\ suspected vaccination failure; shingles on eye; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, 2 years after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and ophthalmic herpes zoster (serious criteria GSK medically significant). On an unknown date, the outcome of the vaccination failure and ophthalmic herpes zoster were unknown.   It was unknown if the reporter considered the vaccination failure and ophthalmic herpes zoster to be related to Shingles vaccine.  Additional details were provided as follows: This case was reported by patient himself/herself. The age at vaccination was not reported. The patient stated he/she had Shingles vaccine and after two years he/she get the shingles on right eyes. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming herpes zoster were unknown at the time of reporting.
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions, medical history and concomitant therapies were not reported. On an unknown date in 2016 (reported as after 29-JUL-2016), the patients received improperly stored (at 0.3 degrees Celsius for a total of five hours and five minutes) doses of GARDASIL 9 lot number M0111117 and M11117 (both were verified as a not valid lot numbers), expiration date: 07-DEC-2017 (strength, dose and route of administration were not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
pt recvd vax JUL93 & FEB94 was found to have a low white blood cell count w/values on subsequent tests ranging from 2800 to 3800;pt is currently seeing a specialist;sx cont
Dizzy, back of tongue swelling, lips numb. She went to Urgent Care and physician on duty confirmed allergic reaction and administered a BENADRYL shot. Fine the next day.
shingles; This spontaneous report has been received from a lawyer regarding a case in litigation referring to a male patient of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications.  On an unknown date in 2015, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, frequency, route, lot number and expiration date were not reported), as prescribed and/or administered by a healthcare provider at a medical center for the long-term prevention of shingles and/or zoster-related conditions.  Subsequent to his zoster vaccine live (ZOSTAVAX) inoculation (date unknown), the patient was treated by a healthcare provider at the medical center for shingles.  As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the event was not reported.
Tachycardia lasting 10 hours.  ER visit with troponin, D dimer and labs drawn,  ekg, chest xray .  IV fluids with meds.    Tachycardia slowly resolved late into the next day.
Patient received Moderna COVID vaccine on 3/22/21 and 4/19/21. On 1/26/22, patient tested positive for COVID. On 1/31/22, patient admitted to our inpatient facility with COVID19 infection, acute kidney injury, dehydration, and generalized weakness. As of today (2/1/22), patient is still admitted in the med/surg unit.
headache; This is a spontaneous report from a non-contactable consumer via a Pfizer sales representative. A 51-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number not provided), via an unspecified route of administration on an unspecified date (age at vaccination unknown) as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient had a headache after the second dose. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient experienced dizziness, lightheaded, throat tightness/SOB, weakness with a blood pressure of 104/54, pulse 90, spO2 98%. Epinephrine was administered. EMS took patient to emergency department in stable condition with blood pressure of 118/84.
Diagnosed with neuro-cardio syncope in August 2006.  Also diagnosed with degenerative disk disease in cervical spine.